Flex Pharma is a biotechnology company that is developing treatments for muscle cramps and spasms associated with severe neurological conditions and exercise-associated muscle cramps. The Company's lead drug product candidate, FLX-787, is currently in exploratory Phase 2 clinical trials in Australia in patients with multiple sclerosis, or MS, and amyotrophic lateral sclerosis, or ALS.It expect to initiate a Phase 2 clinical trial in the United States of FLX-787 in patients with motor neuron disease, primarily with ALS, and another Phase 2 clinical trial in patients with Charcot-Marie-Tooth disease, or CMT. In addition, Flex Pharma launched its consumer product, HOTSHOT, to prevent and treat exercise-associated muscle cramps, or EAMCs.

TypePublic
HQBoston, US
Founded2014
Size (employees)30 (est)
Websiteflex-pharma.com
Flex Pharma was founded in 2014 and is headquartered in Boston, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Key People/Management at Flex Pharma

William McVicar

William McVicar

President and Chief Executive Officer

Flex Pharma Office Locations

Flex Pharma has an office in Boston
Boston, US (HQ)
800 Boylston Street
Show all (1)
Report incorrect company information

Flex Pharma Financials and Metrics

Flex Pharma Revenue

Flex Pharma's revenue was reported to be $1.27 m in FY, 2017
USD

Revenue (Q2, 2018)

424.1 k

Net income (Q2, 2018)

(17.3 m)

EBIT (Q2, 2018)

(17.4 m)

Market capitalization (19-Sep-2018)

8.1 m

Closing stock price (19-Sep-2018)

0.5

Cash (30-Jun-2018)

15.8 m
Flex Pharma's current market capitalization is $8.1 m.
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Revenue

1 m1.3 m

General and administrative expense

4 m4 m4 m18.5 m

R&D expense

40 m4 m4 m17 m

Operating expense total

44.1 m8 m8 m36 m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Revenue

112.7 k599.1 k242.5 k335.5 k178.6 k424.1 k

Cost of goods sold

110.9 k

Gross profit

1.8 k

Gross profit Margin, %

2%
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Cash

33.9 m66.7 m22.4 m19.2 m

Accounts Receivable

12.2 k10.4 k

Inventories

370.4 k908.6 k926 k431.9 k

Current Assets

34.2 m92.2 m62.5 m34.5 m
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q1, 2018Q2, 2018

Cash

110.5 m106 m89.2 m54 m38.9 m27.8 m21.1 m39.1 m21.9 m15.8 m

Accounts Receivable

11.6 k21.8 k19.1 k34.7 k12.6 k17.3 k

Inventories

112.6 k274.3 k230.8 k414.3 k688.2 k418.2 k275.7 k

Current Assets

111.6 m106.8 m100.2 m86.5 m77.4 m69.1 m54.8 m49.1 m25.6 m16.9 m
Annual
USDFY, 2014FY, 2015FY, 2016FY, 2017

Net Income

(8 m)(8 m)(8 m)(34.4 m)

Depreciation and Amortization

12 k49.9 k277.2 k324.5 k

Inventories

(370.4 k)(370.4 k)(370.4 k)22.2 k

Accounts Payable

254.3 k254.3 k254.3 k819.4 k
Quarterly
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018Q2, 2018

Net Income

(92.7 k)(7.1 m)(8.2 m)(9.6 m)(11.4 m)(10.6 m)(8.3 m)(8.2 m)(17.3 m)

Depreciation and Amortization

64.1 k124 k

Inventories

112.6 k274.3 k230.8 k414.3 k(3.3 k)139.2 k

Accounts Payable

567.9 k812.3 k692.7 k1.5 m1.5 m1.3 m818.8 k237 k(859.1 k)
USDY, 2018

Financial Leverage

1.3 x
Show all financial metrics

Flex Pharma Revenue Breakdown

Embed Graph

Flex Pharma revenue breakdown by business segment: 100.0% from Consumer Operations and 0.0% from Other

Report incorrect company information

Flex Pharma Online and Social Media Presence

Embed Graph
Report incorrect company information

Flex Pharma News and Updates

Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Flex Pharma, Inc.; Important Aug. 20 Deadline - FLKS

NEW YORK, Aug. 17, 2018 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Flex Pharma, Inc. between November 6, 2017 and June 12, 2018, both dates inclusive (the "Class Period")....

SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Flex Pharma, Inc. (FLKS)

NEW YORK, June 13, 2018 /PRNewswire/ -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Flex Pharma, Inc. ("Flex" or the "Company") (NASDAQ: FLKS). Such investors are encouraged to obtain additional information and...
Report incorrect company information

Flex Pharma Company Life and Culture

Report incorrect company information